NCT03125707 German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)
| NCT ID | NCT03125707 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Ulm |
| Condition | BCR-ABL1-Negative Myeloid Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,172 participants |
| Start Date | 2013-05 |
| Primary Completion | 2045-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,172 participants in total. It began in 2013-05 with a primary completion date of 2045-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases) To perform morphologic and genetic analyses To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) To assess quality of life
Eligibility Criteria
Inclusion Criteria: Both female and male patients meeting the mentioned inclusion criteria will be included in this registry, because the risk to get a myeloid neoplasm does not depend on a patient's gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the registry: * Patients with BCR-ABL 1-myeloid neoplasia according to WHO classification or IWG MRI criteria * Age ≥ 18 years. There is no upper age limit. * Signed written informed consent. Exclusion Criteria: * Severe neurological or psychiatric disorder interfering with ability to give an informed consent * No consent for registration, storage and handling of the personal data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03125707 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying BCR-ABL1-Negative Myeloid Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03125707 currently recruiting?
Yes, NCT03125707 is actively recruiting participants. Contact the research team at frank.stegelmann@uniklinik-ulm.de for enrollment information.
Where is the NCT03125707 trial being conducted?
This trial is being conducted at Augsburg, Germany, Augsburg, Germany, Bad Saarow, Germany, Baden-Baden, Germany and 11 additional locations.
Who is sponsoring the NCT03125707 clinical trial?
NCT03125707 is sponsored by University of Ulm. The trial plans to enroll 2,172 participants.